Deltu//Review
Markets

Stock market today: US-China truce, Nvidia, Novartis in focus

Tuesday's stock market roundup: the Trump-Xi trade truce, Nvidia's stance on Huang, Novartis's FDA nod, Xpeng and Baidu moves, and a JD.com earnings preview.

2026-11-17 04:08 UTCNov 17, 20263 min read
ItemFigure reported
Dick’s Sporting Goods4 US activist hedge funds exited in Q3
Biotech flagged by an AI stock-picking tool450% revenue beat, 20%+ gain
Novartis CosentyxFDA approval in polymyalgia rheumatica
JD.comQ3 earnings preview
Xpeng / Baidu (Hong Kong)One rallying, one sliding

Several stories are moving the stock market conversation early Tuesday, spanning geopolitics, megacap tech, pharma and Chinese equities. Details are limited for some items, so this roundup sticks to what Investing.com has reported publicly.

Key takeaways

  • Investing.com is tracing how the US and China moved from a tariff war to a trade truce.
  • Nvidia has ruled out a return by Jensen Huang, even as a campaign for it grows, per Investing.com.
  • Novartis won FDA approval for Cosentyx in polymyalgia rheumatica.
  • Xpeng and Baidu shares in Hong Kong moved in opposite directions, and JD.com’s earnings are next.

Trade truce shapes the stock market backdrop

Investing.com published an account of how President Donald Trump and Chinese leader Xi Jinping went from a tariff war to a trade truce. The piece frames a shift that matters for anyone pricing exposure to US-China trade, from exporters to chipmakers to Chinese internet names.

For options desks, a truce typically reshapes the debate over event risk. Whether it changes implied volatility depends on how durable the market judges the deal to be. The reported detail is the arc of the negotiations, not market pricing, so VIX volatility readings are the place to look for a reaction.

Nvidia and the Huang question

According to Investing.com, Nvidia has ruled out a comeback by Huang, while a campaign for his return is growing, with Silicon Valley leaders backing the call. The reporting points to public pressure on one of the market’s most heavily followed companies and a clear response from the company.

Nvidia is a heavy presence in the options market, so governance and leadership stories can draw attention to single-stock positioning. No market reaction figures were reported in the item.

Novartis gets a new Cosentyx indication

Novartis won FDA approval for Cosentyx in polymyalgia rheumatica, according to Investing.com. The approval extends the drug’s label into another inflammatory condition. Patients and prescribers are the most directly affected, and investors in large-cap pharma will watch how the company describes the opportunity in coming updates.

Xpeng up, Baidu down in Hong Kong

Investing.com ran two separate explainers on Hong Kong trading: one asking why Xpeng’s stock is rallying, the other why Baidu’s is sliding. The split shows how differently Chinese electric-vehicle and internet shares were trading in the session. The specific catalysts are in the outlet’s coverage and are not restated here.

JD.com earnings preview

Investing.com’s preview of JD.com’s third-quarter results says investors are focused on e-commerce weakness and AI growth. Earnings previews like this usually lead to heavier option activity around the report as traders position for a move. Watch the company’s commentary on its core retail business against its AI ambitions.

Smaller items: activists and an AI pick

Investing.com also reported that four US activist hedge funds exited Dick’s Sporting Goods in the third quarter amid profit woes. The disclosure suggests activist interest in the retailer has faded for now.

Separately, Investing.com promoted a biotech that its AI models picked first, citing a 450% revenue beat and a gain above 20%. That is a product-driven claim from the outlet’s own tools, not an independent assessment, and readers should treat it that way.

What to watch next

The next moves to follow are the durability of the US-China truce, any further statement from Nvidia, and JD.com’s results. Options pricing around those events will show how much uncertainty traders still see.

Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.

Related